OneMedNet Corporation (ONMD) has formed a new partnership with ViuHealth to expand its autoimmune disease dataset, a move the company says will strengthen its real-world data platform and boost recurring revenue opportunities for life sciences and AI customers.
The collaboration will add ViuHealth's continuous, long-term autoimmune patient data to OneMedNet's iRWD platform, which is built on Palantir Foundry. This includes information on patient symptoms, treatment patterns, flare-ups, and outcomes- details that pharmaceutical companies often need when developing new therapies for chronic autoimmune conditions.
OneMedNet said the expanded dataset will help drugmakers identify patient groups more quickly, support label-expansion studies, train AI models, and generate evidence needed for pricing and reimbursement decisions. Autoimmune diseases affect an estimated 8% of the U.S. population, creating strong demand for deeper, more reliable real-world data.
The company added that partnerships like this support its shift toward subscription-based revenue, as life sciences customers increasingly seek ongoing access to specialized datasets rather than one-time purchases.
ONMD has traded between $0.30 and $4.22 over the past year. The stock is currently trading at $0.74, up 14.88%
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.